TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07811024: SMART-I: SiroMax™ Multi-Center Coronary Artery Lesion Treatment - Safety and Feasibility Study of SiroMax SCB in ISR and DNSV

Sponsor: Tonic Medical, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,038,400

Rescue Site Savings

+$4,648,000

Unlock Full NCT07811024 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07811024 Rescue Dossier →